Assay News and Research

RSS

OvaGene's new molecular diagnostics laboratory receives CLIA-certification

OvaGene Oncology Inc., a molecular diagnostics company specializing in the development and commercialization of personalized gene-based diagnostics for gynecologic cancer, announced today that the company has received Clinical Laboratory Improvement Act (CLIA) certification for their newly constructed state-of-the-art molecular diagnostics laboratory.

20 Sep 2011

Hengrui, Shanghai ChemPartner enter strategic development partnership for monoclonal antibodies

ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, and Jiangsu Hengrui Medicine Co., Ltd., a leading Chinese pharmaceutical company, today announced that Shanghai ChemPartner, a wholly owned subsidiary of ShangPharma, and Hengrui have entered into a strategic partnership for the development of novel therapeutic monoclonal antibodies.

15 Sep 2011

Inovio achieves best-in-class immune responses in PENNVAX-B HIV vaccine Phase I study

Inovio Pharmaceuticals, Inc., a leader in the development of synthetic immunogens against cancers and infectious diseases, announced today that it has achieved best-in-class immune responses in a Phase I clinical study of PENNVAX-B, its product for the prevention of the HIV sub-type prevalent in the US and Europe.

14 Sep 2011

LC-MRM could provide better understanding of multiple myeloma drug resistance

12 Sep 2011

Moffitt researchers employ LC-MRM to detect acquired multiple myeloma drug resistance

"Acquired drug resistance" (ADR) is a major problem encountered in treating some forms of cancer. The ability to monitor the proteins involved in drug resistance has been a hurdle facing cancer researchers. However, a team of researchers at Moffitt Cancer Center, and colleagues, are pioneering promising research utilizing a monitoring technology that could provide a better understanding of ADR and assist in clinical decision-making for developing individualized patient treatments for multiple myeloma.

9 Sep 2011

Thermo Fisher Scientific offers siRNA libraries in Labcyte Echo qualified source plates

Labcyte Inc., a leader in miniaturization technologies for liquid handling, announced today that Thermo Fisher Scientific, the world leader in serving science, is offering the option for customers to receive siRNA (small-interfering RNA) reagent libraries in Labcyte Echo qualified source plates.

From Thermo Fisher Scientific Inc. 7 Sep 2011

Lilly, QIAGEN partner to develop and commercialize companion diagnostic for JAK2 V617F

QIAGEN today announced that it has entered into a partnership with Eli Lilly and Company for the development, manufacturing and commercialization of a molecular companion diagnostic for an early stage investigational compound currently being developed by Lilly. Financial terms of the agreement were not disclosed.

From QIAGEN Manchester Limited 6 Sep 2011

Roche Diagnostics terminates sales and distribution agreement with Response

Response Biomedical Corporation today announced that Roche Diagnostics has terminated, effective September 30, 2011, the sales and distribution agreement between Roche and Response dated June 25, 2008. Under the terms of that agreement and related agreements, Roche Diagnostics had agreed to distribute Response's cardiovascular point-of-care (POC) tests on the RAMP® 200 Reader in the US.

From Roche Sequencing and Life Science 2 Sep 2011

Molecular Devices adds TUNE detection cartridge to SpectraMax Paradigm Detection Platform

Today, Molecular Devices, a leading provider of instruments, software, and consumables for drug discovery and life sciences research, announced the addition of the TUNE detection cartridge to the SpectraMax Paradigm Multi-Mode Microplate Detection Platform. The breakthrough technology of TUNE with wavelength flexibility in a monochromator device and up to 10x the sensitivity will benefit both the research and screening markets.

2 Sep 2011

FDA advisory committee postpones Panel review of Gen-Probe's PROGENSA PCA3 Assay

DiagnoCure, Inc., a life sciences company that develops and commercializes high‐value cancer diagnostic tests, announced today that Gen-Probe Incorporated, its commercial partner for the PCA3 test, received notice from the U.S. Food and Drug Administration (FDA) that the PROGENSA PCA3 Assay will not be reviewed by the Immunology Panel of FDA's Medical Devices Advisory Committee on October 14, 2011 as previously scheduled, but will be reviewed by the Panel at a later date.

30 Aug 2011

PREVENT licenses Amorfix's ProMIS to develop vaccines against misfolded prion diseases

The Pan-Provincial Vaccine Enterprise Inc. (PREVENT), a national Centre of Excellence for Commercialization and Research (CECR), has signed an exclusive license with Amorfix Life Sciences Ltd. of Missisauga, Ontario for the use of their proprietary ProMIS technology in developing vaccines (active immunotherapy) for the treatment of diseases caused by the formation of misfolded prion.

29 Aug 2011

SQI Diagnostics third quarter net loss increases to $2,691,000

SQI Diagnostics Inc., a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced its financial and operational results for the third quarter ended June 30, 2011.

29 Aug 2011

Researchers to develop diagnostic test for folate receptor autoantibody

Researchers at SUNY Downstate Medical Center have received a $50,000 grant from the SUNY Research Foundation Technology Accelerator Fund to develop a diagnostic test for the folate receptor autoantibody. This autoantibody is associated with neural tube defects, subfertility, cerebral folate deficiency in infants and autism spectrum disorders.

26 Aug 2011

IMMY, University of Nevada receive FDA clearance for CrAg Lateral Flow Assay

The Food and Drug Administration has cleared a new diagnostic test that will help save the lives of hundreds of thousands of AIDS patients stricken with cryptococcosis, a fungal meningitis.

25 Aug 2011

FDA clears IQuum's Liat influenza A/B assay, analyzer

IQuum, Inc. announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market the Liat Influenza A/B Assay and the Liat Analyzer.

23 Aug 2011

Phadia launches new allergy and autoimmunity testing instruments

Today Phadia, the global leader in allergy and autoimmune related diseases diagnostics, announced the launch of Phadia's new allergy and autoimmunity testing instruments; Phadia 2500 and Phadia 5000.

23 Aug 2011

Health Canada grants medical device licence to Gen-Probe's PANTHER system

Gen-Probe Incorporated announced today that Health Canada has granted the Company a medical device license for the PANTHER system, a fully automated and integrated molecular testing system designed with the flexibility to handle a wide range of testing needs.

23 Aug 2011

Assay News and Research

OvaGene's new molecular diagnostics laboratory receives CLIA-certification

Hengrui, Shanghai ChemPartner enter strategic development partnership for monoclonal antibodies

Inovio achieves best-in-class immune responses in PENNVAX-B HIV vaccine Phase I study

LC-MRM could provide better understanding of multiple myeloma drug resistance

Moffitt researchers employ LC-MRM to detect acquired multiple myeloma drug resistance

Thermo Fisher Scientific offers siRNA libraries in Labcyte Echo qualified source plates

Lilly, QIAGEN partner to develop and commercialize companion diagnostic for JAK2 V617F

Roche Diagnostics terminates sales and distribution agreement with Response

Molecular Devices adds TUNE detection cartridge to SpectraMax Paradigm Detection Platform

FDA advisory committee postpones Panel review of Gen-Probe's PROGENSA PCA3 Assay

PREVENT licenses Amorfix's ProMIS to develop vaccines against misfolded prion diseases

SQI Diagnostics third quarter net loss increases to $2,691,000

Researchers to develop diagnostic test for folate receptor autoantibody

IMMY, University of Nevada receive FDA clearance for CrAg Lateral Flow Assay

FDA clears IQuum's Liat influenza A/B assay, analyzer

Phadia launches new allergy and autoimmunity testing instruments

Health Canada grants medical device licence to Gen-Probe's PANTHER system

IVAX Diagnostics net revenues decrease 0.4% to $4,375,000 for quarter ended June 30, 2011

IRSF announces new Rett syndrome translational research awards

Health Canada grants medical device license to Gen-Probe's PROGENSA PCA3 assay

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News